Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALA: Neratinib plus capecitabine vs lapatinib plus capecitabine in HER2-positive metastatic breast cancer
KCT0001143Phase 3Recruiting
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Feb 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in HER2-enriched breast cancer (HER2+) comparing Neratinib plus capecitabine with Lapatinib plus capecitabine (2 arms). Started Feb 2014; status: recruiting.
02
Drugs
neratiniblapatinibcapecitabine
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on KCT0001143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001143.